BOSTON and LONDON, May 15, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology company developing novel Antibody Drug Conjugates (ADCs) with immuno-oncology payloads for ...

A novel topical formulation of a BRAF inhibitor significantly reduced acneiform rash associated with anti–epidermal growth factor receptor (EGFR) therapies in patients with colorectal cancer ...

The San Diego-based biotech has plans to take its myostatin inhibitor lead candidate, IBIO-600, to a Phase I study in early 2026, adds the CEO. The development of therapies to prevent muscle loss is ...

Department of Pharmacy, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, China Introduction: Prior cohort studies reported paradoxical results between proton pump inhibitor (PPI) ...

Kinases are considered effective targets for drug development, especially with the notable success of kinase inhibitors in cancer treatment. Nonetheless, their capabilities in treating ...

1Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Chicago, Chicago, Illinois. *Corresponding Author: Hilary A. Kenny, Department of Obstetrics and Gynecology, ...

State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing ...

Some examples are Daypro, Indocin, Lodine, Naprosyn, Relafen, and Voltaren. Cox-2 inhibitors are a kind of NSAID. They were thought to have fewer stomach and intestinal side effects than standard ...

Led by AbbVie’s Humira, biologic TNF inhibitors transformed the treatment of autoimmune diseases over the past 20 years. However, the biologic modality can cause adverse effects and loss of ...

Image credit: Shutterstock / LCV Sanofi will halt the development of its oral tumour necrosis factor (TNF) inhibitor balinatunfib as a monotherapy after it failed to reach the primary endpoint in a ...

HARMONi-6 is evaluating ivonescimab in combination with platinum-based chemotherapy compared with tislelizumab, a PD-1 inhibitor, in combination with platinum-based chemotherapy in patients with ...